MRI/TRUS fusion software-based targeted biopsy: the new standard of care?

Details

Serval ID
serval:BIB_039DA3FB7A5A
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
MRI/TRUS fusion software-based targeted biopsy: the new standard of care?
Journal
Minerva Urologica e Nefrologica
Author(s)
Manfredi M., Costa Moretti T.B., Emberton M., Villers A., Valerio M.
ISSN
1827-1758 (electronic)
ISSN-L
0393-2249
Publication state
Published
Issued date
2015
Peer-reviewed
Oui
Volume
67
Number
3
Pages
233-246
Language
english
Notes
Publication types: Journal ArticlePublication Status: ppublishDocument Type: Review
Abstract
The advent of multiparametric MRI has made it possible to change the way in which prostate biopsy is done, allowing to direct biopsies to suspicious lesions rather than randomly. The subject of this review relates to a computer-assisted strategy, the MRI/US fusion software-based targeted biopsy, and to its performance compared to the other sampling methods. Different devices with different methods to register MR images to live TRUS are currently in use to allow software-based targeted biopsy. Main clinical indications of MRI/US fusion software-based targeted biopsy are re-biopsy in men with persistent suspicious of prostate cancer after first negative standard biopsy and the follow-up of patients under active surveillance. Some studies have compared MRI/US fusion software-based targeted versus standard biopsy. In men at risk with MRI-suspicious lesion, targeted biopsy consistently detects more men with clinically significant disease as compared to standard biopsy; some studies have also shown decreased detection of insignificant disease. Only two studies directly compared MRI/US fusion software-based targeted biopsy with MRI/US fusion visual targeted biopsy, and the diagnostic ability seems to be in favor of the software approach. To date, no study comparing software-based targeted biopsy against in-bore MRI biopsy is available. The new software-based targeted approach seems to have the characteristics to be added in the standard pathway for achieving accurate risk stratification. Once reproducibility and cost-effectiveness will be verified, the actual issue will be to determine whether MRI/TRUS fusion software-based targeted biopsy represents anadd-on test or a replacement to standard TRUS biopsy.
Pubmed
Web of science
Create date
24/11/2015 18:20
Last modification date
20/08/2019 13:25
Usage data